KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Takeda Pharmaceutical (TAK) Gross Margin (2017 - 2025)

Historic Gross Margin for Takeda Pharmaceutical (TAK) over the last 9 years, with Q4 2025 value amounting to 66.34%.

  • Takeda Pharmaceutical's Gross Margin rose 27500.0% to 66.34% in Q4 2025 from the same period last year, while for Dec 2025 it was 66.48%, marking a year-over-year increase of 14200.0%. This contributed to the annual value of 17.92% for FY2025, which is 486200.0% down from last year.
  • As of Q4 2025, Takeda Pharmaceutical's Gross Margin stood at 66.34%, which was up 27500.0% from 66.03% recorded in Q3 2025.
  • In the past 5 years, Takeda Pharmaceutical's Gross Margin registered a high of 216.46% during Q3 2022, and its lowest value of 59.22% during Q4 2022.
  • Moreover, its 5-year median value for Gross Margin was 67.04% (2021), whereas its average is 74.51%.
  • As far as peak fluctuations go, Takeda Pharmaceutical's Gross Margin tumbled by -1667300bps in 2021, and later skyrocketed by 1491100bps in 2022.
  • Quarter analysis of 5 years shows Takeda Pharmaceutical's Gross Margin stood at 68.78% in 2021, then decreased by -14bps to 59.22% in 2022, then rose by 7bps to 63.64% in 2023, then dropped by 0bps to 63.59% in 2024, then grew by 4bps to 66.34% in 2025.
  • Its Gross Margin was 66.34% in Q4 2025, compared to 66.03% in Q3 2025 and 66.47% in Q2 2025.